Dr. Reddy's Laboratories updates on PAI of formulations facility
Drug Approval

Dr. Reddy's Laboratories updates on PAI of formulations facility

The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.

  • By IPP Bureau | July 08, 2022

Dr. Reddy’s Laboratories Limited has informed that the United States Food & Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) at formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh.

The inspection was conducted from 30th June, 2022 to 7th July, 2022 and the company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International